Table 4 Comparison between LV function, ECV and myocardial strain before and after 6-months anti-hypertension drug therapy
Before treatment | After treatment | P value | |
|---|---|---|---|
EF | 44.6 ± 22.3 | 52.4 ± 18.9 | 0.02 |
LVEDVI (ml/m2) | 96.9 (67.7) | 74.8 (40.1) | 0.06 |
LVSVI (ml/m2) | 40.0 ± 16.4 | 40.1 ± 13.8 | 0.85 |
LVMI(g/m2) | 106.5 (31.2) | 97.6 (36.2) | 0.18 |
EDWT (cm) | 1.2 (0.2) | 1.1 (0.3) | 0.03 |
ECV | |||
Mean | 0.27 (0.04) | 0.25 (0.04) | 0.000 |
Base | 0.29 ± 0.04 | 0.25 ± 0.04 | 0.000 |
Middle | 0.25 (0.01) | 0.24 (0.01) | 0.001 |
Apex | 0.25 (0.01) | 0.24 (0.01) | 0.71 |
RS | |||
Global | 16.8 ± 8.9 | 22.7 ± 9.5 | 0.01 |
Base | 20.7 ± 11.1 | 29.5 ± 16.7 | 0.06 |
Middle | 11.0 (17.0) | 20.2 (14.3) | 0.027 |
Apex | 13.6 (17.9) | 20.4 (22.3) | 0.64 |
CS | |||
Global | −13.4 ± 5.6 | −16.0 ± 4.6 | 0.03 |
Base | −9.9 (10.5) | −10.9 (7.8) | 0.02 |
Middle | −12.0 (11.9) | −17.4 (8.3) | 0.16 |
Apex | −16.2 ± 6.5 | −19.6 ± 5.2 | 0.05 |
LS | |||
Global | −6.9 (6.0) | −9.0 (5.4) | 1.00 |
Base | −5.4 (5.0) | −5.2 (13.1) | 0.13 |
Middle | −6.4 (6.4) | −8.7 (5.8) | 0.50 |
Apex | −10.7 (8.0) | −12.0 (6.3) | 0.12 |